In this review:
FVIII mutation and inhibitor development in nonsevere haemophilia A
Risk factors for inhibitor development in nonsevere haemophilia A
European monitoring of inhibitor development in haemophilia A/B
Changes in inhibitor incidence in severe haemophilia A
N9-GP for bleeding episodes in haemophilia B
Severe thrombocytopenia in mice
3- vs 4-factor prothrombin complex concentrates and rivaroxaban pharmacodynamics
Secondary prevention of recurrent VTE
Subsegmental PE is less severe subset of PE
CDR to guide anticoagulation in first unprovoked VTE
Imaging legs in suspected DVT
Rivaroxaban dose in renal impairment
RVT as a predictor of recurrent VTE and PTS
Please login below to download this issue (PDF)